Future Science Group today announced that it will provide free access to three of its peer-reviewed, cancer-focused journals for the remainder of 2015. The journals, Hepatic Oncology, Melanoma Management, and the International Journal of Endocrine Oncology present the latest findings in their area of research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field.
“Given the critical importance of emerging research to every practitioner treating patients with cancer, we are very pleased to provide individuals with better access to new sources of quality information,” said Phil Garner, Managing Director of Future Science Group. “While the journals are relatively new, each offers in depth coverage of an area of cancer that demands more attention and resources.”
Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The quarterly journal also highlights significant advances in basic and translational research, and places them in context for future therapy.
Melanoma Management launched in August 2014 and focuses on the clinical aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. Published quarterly, Melanoma Management delivers an accessible overview of current and future melanoma management options in a concise format that is ideal for the busy clinician. The journal welcomes the unsolicited submission of article proposals and original research manuscripts.
International Journal of Endocrine Oncology is a quarterly, peer-reviewed journal that helps the clinician to keep up to date with best practice in a fast-moving field that covers a broad range of diseases, both malignant and benign. It presents research findings in diagnosis and management of endocrine cancer, including tumors of hormone-secreting glands, such as the pituitary, thyroid, pancreatic and adrenal glands, along with neuroendocrine tumors. Independent drug evaluations assess newly approved medications and their role in clinical practice.
All of the journals welcome the unsolicited submission of article proposals and original research manuscripts. Select content can be accessed from the whole of Future Science Group’s Oncology collection. Plus, via Oncology Central, Future Science Group’s free eCommunity for oncology professionals, users can access breaking news, articles and other essential current information, all aimed and selected by fellow trusted clinicians.